BRCA1 and ovarian carcinoma: Importantly, the BARD1-CA125 261-sample-fitted model reached a sensitivity of 0.99 for the no-mutation (wt) and “other” groups (other than BRCA1/2 or BARD1 group of OC) and a sensitivity of 1 for the ovarian cancers with BRCA1/2 or BARD1 mutations.